Morales et al. reported that the specificities of anti-CdtB and anti-vinculin for differentiating IBS-D from IBD were 93.5% and 90.9%, with sensitivities of 43.0% and 52.2%, respectively (Morales et al., 2019). This evidence concerns the gene VCL and inflammatory bowel disease.